<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/F9F1D136-12E3-4BE4-9668-0C9BC4A7C1BF"><gtr:id>F9F1D136-12E3-4BE4-9668-0C9BC4A7C1BF</gtr:id><gtr:name>Bangor University</gtr:name><gtr:department>The Finance Officer (Caederwen)</gtr:department><gtr:address><gtr:line1>Bangor University</gtr:line1><gtr:line4>Bangor</gtr:line4><gtr:line5>Gwynedd</gtr:line5><gtr:postCode>LL57 2DG</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/F9F1D136-12E3-4BE4-9668-0C9BC4A7C1BF"><gtr:id>F9F1D136-12E3-4BE4-9668-0C9BC4A7C1BF</gtr:id><gtr:name>Bangor University</gtr:name><gtr:address><gtr:line1>Bangor University</gtr:line1><gtr:line4>Bangor</gtr:line4><gtr:line5>Gwynedd</gtr:line5><gtr:postCode>LL57 2DG</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/88AB4462-1160-47C1-B209-E1A26604CFF6"><gtr:id>88AB4462-1160-47C1-B209-E1A26604CFF6</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Cross</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0400383"><gtr:id>1951E03D-8E11-4F07-AE71-B109ADF85A5E</gtr:id><gtr:title>Gene expression and intracellular signalling pathways regulating angiogenesis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400383</gtr:grantReference><gtr:abstractText>Angiogenesis is the biological process whereby new capillary blood vessels are formed from pre-existing ones. This process is important in both normal development and in the development of diseases such as cancer, arthritis and atherosclerosis (narrowing of the cardiac artery due to fatty deposits) which affect millions of people throughout the world. Blood vessels are composed of an inner lining of endothelial cells. These cells respond to various growth factors such as vascular endothelial growth factor (VEGF) which stimulates angiogenesis. Tumours require an adequate blood supply to grow and produce VEGF to stimulate the endothelial cells to grow towards the tumour and provide oxygen and nutrients. VEGF action has also been implicated in development of arthritis and atherosclerosis. I have previously studied the expression pattern of thousands of genes when endothelial cells are exposed to VEGF. By manipulating the conditions, endothelial cells could be induced to grow or to form tubular-like structures, reminiscent of capillaries, in response to VEGF. I have identified a number of genes whose expression regulates these different stages of angiogenesis. This project will determine the mechanism of action of these genes using a number of cellular models which mimick angiogenesis in the body. These models will allow one to alter the activity of genes and observe the effect of this on the endothelial cell. We will also analyse tissue sections representing specimens of tumours, atherosclerotic arteries and arthritic joints to determine the expression of selected genes. This project will reveal the function of genes critical to endothelial cell physiology. These genes will represent new targets for drug development to prevent and manage diseases such as cancer, atherosclerosis and arthritis.</gtr:abstractText><gtr:technicalSummary>Angiogenesis defines the formation of new blood vessels from pre-existing ones. It is vital for normal physiological development and in the pathology of a number of diseases such as cancer, rheumatoid arthritis and atherosclerosis. Indeed, recent clinical data, confirming proof of principle, has shown that by inhibiting the availability of VEGF, it is possible to prevent the growth of a number of solid tumours. 
The aim of this project is to determine the biological function and mechanism of action of a number of genes/proteins in endothelial cells during angiogenesis. I have performed a detailed microarray analysis of telomerase immortalized human dermal microvascular (TIME) cells either proliferating on a fibronectin matrix or undergoing tubular morphogenesis in a collagen gel in response to VEGF. A comprehensive time-course study allowed us to use bioinformatic analysis to identify genes whose expression was either differentially regulated during either proliferation or tubular morphogenesis, in response to VEGF. Real-time PCR has confirmed our initial data. I have identified approximately 30 genes and a number of ESTs which are potential candidates for regulating the angiogenic response of endothelial cells. This project will utilize a number of in vitro models of angiogenesis to allow the functional analysis of our selected genes on endothelial cell physiology.
(I) TIME/HDMEC cells and gene manipulation. Primary or telomerase immortalized human microvascular endothelial cells will be be used for manuipulation of selected genes using classical over-expression or the novel siRNA technique. The effect on endothelial cell physiology will then be studied.
(II) Embryoid bodies. These aggregates of murine stem cells will be utilized to determine the effect of specific gene manipulation, using over-expression or siRNA, on vasculogenesis and angiogenesis in response to growth factors.
(III) Tissue arrays. These represent numerous samples of patholigical tissue on a glass slide allowing one to perform in situ and immunofluorescence staining to analyse the expression of selected genes/proteins in the endothelium of diseased/normal samples.
Selected genes will be taken forward for in vivo gene targeting in mice to study the effect on physiological blood vessel formation and development of diseases using animal models.

By elucidating exactly how growth factors, such as VEGF, stimulate an angiogenic response at the molecular level, we will be able to design the next generation of anti-angiogenic drugs aimed at preventing and controlling diseases which afflict the majority of the population.</gtr:technicalSummary><gtr:fund><gtr:end>2008-04-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-05-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>233291</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biological Sciences Liverpool</gtr:department><gtr:description>University of Liverpool</gtr:description><gtr:id>D5776F59-831C-4613-AB7D-963949672E8D</gtr:id><gtr:impact>Holmes, K., Chapman, E.A, See, V., and Cross M.J. (2010). VEGF stimulates RCAN1.4 expression in endothelial cells via a pathway requiring Ca2+/Calcineurin and Protein Kinase C-?. PLoS One 5(7):e11435</gtr:impact><gtr:partnerContribution>Confocal image analysis</gtr:partnerContribution><gtr:piContribution>Generated majority of the data for a publication building on previous work from the MRC grant</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>162482</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2011-05-02</gtr:end><gtr:fundingOrg>North West Cancer Research (NWCR)</gtr:fundingOrg><gtr:id>5E0BE70A-05C6-4375-A058-EB0A80A89B86</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-05-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Developed method to design qRT-PCR primers for analysing efficiency of siRNA mediated gene silencing</gtr:description><gtr:id>A93CE794-B0E9-4071-AD63-2ABD7CD51920</gtr:id><gtr:impact>Development of method which was published:

Holmes, K., Williams, M.C., Chapman, E.A. and Cross M.J. (2010). Detection of siRNA induced mRNA silencing by RT-qPCR: considerations for experimental design. BMC Research Notes. 3:53</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>real-time PCR</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FFC92DE4-9822-4E4C-9703-45CBF9E73BB5"><gtr:id>FFC92DE4-9822-4E4C-9703-45CBF9E73BB5</gtr:id><gtr:title>Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b8bedf606cf518a37d14a3a11256c70c"><gtr:id>b8bedf606cf518a37d14a3a11256c70c</gtr:id><gtr:otherNames>Holmes K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8BC8C8D2-596E-4817-8D13-2E99BF74618C"><gtr:id>8BC8C8D2-596E-4817-8D13-2E99BF74618C</gtr:id><gtr:title>Detection of siRNA induced mRNA silencing by RT-qPCR: considerations for experimental design.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b8bedf606cf518a37d14a3a11256c70c"><gtr:id>b8bedf606cf518a37d14a3a11256c70c</gtr:id><gtr:otherNames>Holmes K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400383</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D4FDB752-4E9C-491F-9C63-B7D7F6F95417</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Cardiovascular</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>